T 2149/19 (Dabigatran etexilate/KRKA) of 25.06.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T214919.20210625
- Date of decision
- 25 June 2021
- Case number
- T 2149/19
- Online on
- 14 July 2021
- Petition for review of
- -
- Application number
- 11732405.3
- IPC class
- A61K 9/50
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- PHARMACEUTICAL ORAL DOSAGE FORMS COMPRISING DABIGATRAN ETEXILATE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
- Applicant name
- KRKA, tovarna zdravil, d.d., Novo mesto
- Opponent name
- Generics [UK] Ltd
Eder, Michael
Georg Kalhammer/Stephan Teipel - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56European Patent Convention Art 123(2)Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Inventive step - main request (no)
Inventive step - auxiliary request (yes)
Late-filed request - submitted with the statement of grounds of appeal
Amendments - allowable (yes) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent on the basis of the set of claims filed as auxiliary request 1 with the statement of grounds of appeal on 28 October 2019 and a description to be adapted.